<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849095</url>
  </required_header>
  <id_info>
    <org_study_id>AIFA-ASMA-BF-001</org_study_id>
    <secondary_id>EudraCT number: 2008-004127-36</secondary_id>
    <nct_id>NCT00849095</nct_id>
  </id_info>
  <brief_title>Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma</brief_title>
  <official_title>As Needed Budesonide/Formoterol Combination Versus Regular Budesonide/Formoterol Combination Plus as Needed Terbutaline in Mild-Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Ferrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study No.001 about Budesonide/Formoterol use in ASthMA sponsored by Agenzia Italiana del
      FArmaco (Italian Drug Agency) (AIFA-ASMA-BF-001) The aim of the study is to verify whether
      asthma not controlled by low doses inhaled corticosteroids, thus in need for step up therapy,
      can be equally controlled by guidelines recommended regular bid treatment with long acting
      beta agonist/inhaled corticosteroid (ICS/LABA) combination or the symptom driven use of an
      ICS/LABA combination in the absence of maintenance therapy. The study is designed to be able
      to evaluate the non inferiority of regular placebo plus prn inhaled budesonide/formoterol
      (experimental treatment) versus regular, twice daily 160/4.5 mcg inhaled
      budesonide/formoterol combination plus prn inhaled terbutaline (guidelines recommended
      treatment).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a problem worldwide, with an estimated 300 million affected individuals.There is
      evidence that asthma prevalence has been increasing in the last decades in some countries,
      including Italy. Analyses of the cost of asthma lead to conclude that the burden of the
      disease depend on the extent to which exacerbations are avoided since emergency treatment is
      more expensive than regular treatment.

      Based on solid evidence, international guidelines recommend regular treatment with low dose
      ICS for mild persistent asthma and treatment with combination therapy [low dose ICS plus
      long-acting beta2-agonists (LABA)] for patients with asthma not controlled by low doses ICS
      alone. Recent studies have undermined the axiom that treatment with ICS must be regular to
      achieve and maintain asthma control, as equivalent control has been obtained either with prn
      use of an inhaled combination of a short acting beta2 agonist (SABA) and an ICS, or with a
      short course of 10 days high dose ICS at the start of exacerbations. In moderate-severe
      asthma regularly treated with inhaled ICS/LABA combination, the symptom-driven use of the
      same inhaled ICS/LABA combination as reliever is superior to the symptom-driven use of SABA
      or LABA alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison between groups of the relative risk for treatment failure</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of treatment failures</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first treatment failure</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differences between groups of lung function parameters, quality of life, symptoms score, use of as needed medication, adverse events</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">860</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>as needed medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>guideline treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol combination (PRN)</intervention_name>
    <description>budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks</description>
    <arm_group_label>as needed medication</arm_group_label>
    <other_name>budesonide/formoterol combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol combination</intervention_name>
    <description>budesonide/formoterol 160/4.5 mcg 1 inhalation bid</description>
    <arm_group_label>guideline treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>bid inhaled placebo</description>
    <arm_group_label>as needed medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbutaline</intervention_name>
    <description>as needed terbutaline 500 mcg for a period of 52 weeks</description>
    <arm_group_label>guideline treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female out-patient aged from 18 years to 65 years

          -  Clinical diagnosis of moderate persistent asthma for at least 6 months, according to
             GINA revised version 2006 guidelines

          -  Post-bronchodilator forced expiratory volume (FEV1) at least 80% of the predicted

          -  Either positive methacholine challenge test (PC20 FEV1&lt; 4mg/ml or PD20 FEV1&lt;0.8 mg) or
             positive response to the reversibility test in the last year

          -  Asthma either not adequately controlled with low-dose (≤500 mcg beclomethasone or
             equivalent) inhaled corticosteroids (ICS) or controlled by bid inhaled combination of
             low-dose ICS/long acting beta-2 agonists (LABA)

          -  A co-operative attitude and ability to be trained to correctly use the dry powder
             inhalator and to complete the diary cards

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Inability to carry out pulmonary function testing

          -  Moderate severe asthma associated with reduced lung function

          -  History of near-fatal asthma and/or admission intensive care unit because of asthma

          -  3 or more courses of oral corticosteroids or hospitalization for asthma during the
             previous year

          -  Diagnosis of COPD as defined by the GOLD guidelines

          -  Evidence of severe asthma exacerbation or symptomatic infection of the airways in the
             previous 8 weeks

          -  Current smokers or recent (less than one year) ex-smokers, defined as smoking at least
             10 pack/years

          -  History or current evidence of heart failure, coronary artery disease, myocardial
             infarction, severe hypertension, or cardiac arrhythmias

          -  Diabetes mellitis

          -  Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft
             (CABG) during the previous six months

          -  Abnormal ECG

          -  Clinically significant or unstable concurrent diseases: uncontrolled hyperthyroidism,
             significant hepatic impairment, poorly controlled pulmonary disease (tuberculosis,
             active mycotic infection of the lung), gastrointestinal (e.g., active peptic ulcer),
             neurological or haematological autoimmune diseases

          -  Malignancy

          -  Any chronic diseases with prognosis &lt; 2 years

          -  Pregnant or lactating females or not able to exclude pregnancy during the study period

          -  History of alcohol or drug abuse

          -  Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or
             beta-blockers as regular use

          -  Allergy, sensitivity or intolerance to study drugs and/or study drug formulation
             ingredients

          -  Patients unlikely to comply with the protocol or unable to understand the nature,
             scope and possible consequences of the study

          -  Patients who received any investigational new drug within the last 12 weeks

          -  Patients who have been previously enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Papi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli Studi di Ferrara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale regionale Umberto I, Unità Operativa di Allergologia</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione S. Maugeri - IRCCS -dipartimento di Pneumologia riabilitativa</name>
      <address>
        <city>Cassano delle Murge</city>
        <state>BA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Mediche-Unità Operativa di Pneumologia</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi, Unità Operativa di Pneumologia</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Catania, Unità operativa di Pneumologia</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Magna Grecia Catanzaro, unità operativa di Pneumologia</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni Pierantoni, azienda Ospedaliera di Forlì, Unitaà operativa di Pneumologia</name>
      <address>
        <city>Forlì</city>
        <state>FC</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIVERSITà DEGLI STUDI DI FERRARA, CLINICA DI MALATTIE DELL'APPARATO RESPIRATORIO</name>
      <address>
        <city>Ferrara</city>
        <state>FE</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Foggia, ospedale pneumologico D'Avanzo, unità operativa di malattie dell'apparato respiratorio</name>
      <address>
        <city>Foggia</city>
        <state>FG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospadale San Carlo Borromeo - Unità operativa di Pneumologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale città di Sesto San Giovanni, Unità operativa di Pneumologia</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Modena e Reggio Emilia, Unità operativa di Pneumologia</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Palermo, Ospedale &quot;V. Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <state>Pa</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Padova, dipartimento di Pneunmologia</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Padova, Medicina del Lavoro</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Pisa, Ospedale Cisanello, unità operativa di Pneumologia</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli stiudi di Parma, unità operativa di Pneumologia</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione S Maugeri, Dipartimento di Allergologia</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Pavia, dipartimento di Pneumologia</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>università Cattolica del Sacro Cuore, Columbus, unità operativa di allergologia</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore, Policlinico Gemelli, unità operativa di Pneumologia</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Roma La Sapienza, servizio di Fisiopatologia respiratoria</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Perugia -Terni, Medcina del lavoro Terni</name>
      <address>
        <city>Terni</city>
        <state>TI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Torino, Dipartimento di scienze biomediche ed oncologia umana</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Cattinara, unità operativa di pneumologia</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Bussolengo, Unità operativa di Pneumologia</name>
      <address>
        <city>Bussolengo</city>
        <state>VR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>azienda universitaria-ospedaliera istituti ospitalieri di Verona, unità operativa di Allergologia</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio Pneumologico ASL Brindisi</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Università degli stuidi di Napoli, unità Operativa di Pneumologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giuseppina Bertorelli</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Roma Tor Vergata, unità di malattie dell'apparato Respiratorio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2009</study_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Ferrara</investigator_affiliation>
    <investigator_full_name>Alberto Papi, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Adult</keyword>
  <keyword>Asthma</keyword>
  <keyword>Bronchodilator Agents</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Double-Blind Method</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Ethanolamines</keyword>
  <keyword>Female</keyword>
  <keyword>Forced Expiratory Volume</keyword>
  <keyword>Humans</keyword>
  <keyword>Male</keyword>
  <keyword>Terbutaline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

